**STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies**

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1. *(a)* Indicate the study’s design with a commonly used term in the title or the abstract—Done so in Title and Abstract  
*(b)* Provide in the abstract an informative and balanced summary of what was done and what was found—Done so in Abstract |
| **Introduction** | 2. Explain the scientific background and rationale for the investigation being reported—Done so in Introduction section |
| **Methods** | 3. State specific objectives, including any prespecified hypotheses—Objectives have been stated in Introduction section |
| **Methods** | 4. Present key elements of study design early in the paper—Indicated in the Method section |
| **Methods** | 5. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection—Indicated in the Method section |
| **Methods** | 6. *(a)* Give the eligibility criteria, and the sources and methods of selection of participants—Indicated in the Method section |
| **Methods** | 7. Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable—Indicated in Method section |
| **Methods** | 8. *(a)* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group—Indicated in Method section |
| **Bias** | 9. Describe any efforts to address potential sources of bias—NA |
| **Study size** | 10. Explain how the study size was arrived at—Indicated in the Method Section |
| **Quantitative variables** | 11. Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why—Indicated in the Method and Data Analysis sections |
| **Statistical methods** | 12. *(a)* Describe all statistical methods, including those used to control for confounding  
*(b)* Describe any methods used to examine subgroups and interactions  
*(c)* Explain how missing data were addressed  
*(d)* If applicable, describe analytical methods taking account of sampling strategy  
*(e)* Describe any sensitivity analyses |
| **Results** | 13. *(a)* Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed—Above indicated in the Results section  
*(b)* Give reasons for non-participation at each stage—participation rate was 100% in our study  
*(c)* Consider use of a flow diagram—NA |
| **Descriptive data** | 14. *(a)* Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders—Above indicated in Result section and Table 1  
*(b)* Indicate number of participants with missing data for each variable of interest |
## Outcome data

15* Report numbers of outcome events or summary measures—There is no missing data in our study.

## Main results

16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included.

(b) Report category boundaries when continuous variables were categorized

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Above found in the Results section and Tables 1-3

## Other analyses

17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses—Done so in Results section

## Discussion

### Key results

18 Summarise key results with reference to study objectives—Done so in Discussion section

### Limitations

19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias—Done so in Discussion section

### Interpretation

20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence—Done so in Discussion section

### Generalisability

21 Discuss the generalisability (external validity) of the study results—Done so in Discussion section

## Other information

### Funding

22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based—No funding was required for this study

*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.